Tower Research Capital LLC TRC Makes New Investment in Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Tower Research Capital LLC TRC purchased a new position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,558 shares of the company’s stock, valued at approximately $44,000.

Other institutional investors have also modified their holdings of the company. Amalgamated Bank purchased a new stake in shares of Neumora Therapeutics during the 4th quarter worth $29,000. New York State Common Retirement Fund purchased a new stake in shares of Neumora Therapeutics during the 4th quarter worth $118,000. Strs Ohio purchased a new stake in shares of Neumora Therapeutics during the 4th quarter worth $54,000. SG Americas Securities LLC purchased a new stake in shares of Neumora Therapeutics during the 4th quarter worth $108,000. Finally, Citigroup Inc. purchased a new stake in shares of Neumora Therapeutics during the 3rd quarter worth $203,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

Neumora Therapeutics Price Performance

NMRA traded up $0.12 on Thursday, reaching $9.22. The company had a trading volume of 1,073,481 shares, compared to its average volume of 483,337. Neumora Therapeutics, Inc. has a 1 year low of $8.82 and a 1 year high of $21.00. The stock has a 50-day moving average price of $14.07 and a 200-day moving average price of $14.07.

Neumora Therapeutics (NASDAQ:NMRA) last announced its earnings results on Thursday, March 7th. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.05. As a group, sell-side analysts anticipate that Neumora Therapeutics, Inc. will post -1.48 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on NMRA shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $31.00 price objective on shares of Neumora Therapeutics in a research report on Thursday, March 28th. William Blair reaffirmed an “outperform” rating on shares of Neumora Therapeutics in a research report on Friday, April 12th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Neumora Therapeutics from $20.00 to $22.00 and gave the stock an “overweight” rating in a research report on Monday, March 18th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $22.57.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.